Tempus AI, Inc. (TEM) Earnings Call Transcript & Summary

May 5, 2026

NASDAQ US Health Care Life Sciences Tools and Services earnings 32 min

What were the key takeaways from Tempus AI, Inc.'s May 5, 2026 earnings call?

Tempus AI reported strong financial results for Q1 2026, with revenue reaching $348.1 million, a 36% increase year-over-year. The company's diagnostic revenue was $261.1 million, driven by oncology business growth. Data and applications revenue was $87 million, up 40.5% YoY. Tempus raised its full-year guidance to a range of $1.5 billion to $1.6 billion, with adjusted EBITDA expected at $65 million. This guidance increase, along with robust growth in both diagnostics and data businesses, could positively impact the stock.

What topics did Tempus AI, Inc. cover?

  • Revenue Growth: Revenue for Q1 2026 was $348.1 million, up 36% year-over-year. Diagnostic revenue grew by 35%, with oncology unit growth at 28%. Data and applications revenue increased by 40.5%, driven by data licensing and modeling business insights.
  • Guidance Increase: Tempus increased its full-year revenue guidance to $1.5 billion to $1.6 billion, with adjusted EBITDA expected at $65 million. This reflects strong performance across main business segments.
  • Pharma Collaborations: Tempus expanded its pharma collaborations, adding Merck and expanding with Gilead. These strategic partnerships are expected to enhance data business growth.
  • FDA Submissions: No significant updates on FDA submissions for XF. An amendment for tumor-only cases is expected imminently, which could accelerate migration to ADLT version.
  • Cash Flow and EBITDA: Cash flow from operations was down, but significant improvement is expected in Q2. Adjusted EBITDA is projected to reach $65 million for the year.

What were Tempus AI, Inc.'s May 5, 2026 results?

  • Revenue: $348.1M (vs $256M YoY, +36%)
  • Diagnostic Revenue: $261.1M (+35% YoY)
  • Data and Applications Revenue: $87M (+40.5% YoY)
  • Adjusted EBITDA: $65M (guidance) (Increased from prior guidance)
  • MRD Growth: 500% (Limited by reimbursement)

Tempus AI's strong Q1 performance and increased guidance reinforce its growth trajectory, particularly in diagnostics and data applications. Strategic pharma collaborations and a robust pipeline support long-term growth. Investors should monitor FDA submission outcomes and reimbursement developments as potential catalysts or risks.

Earnings Call Speaker Segments

Liz Krutoholow

executive
#1

Thanks. Good afternoon, everyone. I'd like to welcome you to the Tempus conference call for the first quarter of 2026; results for the quarter that closed on March 31st, 2026 were made public by Tempus this afternoon. You can find the press release, the quarter overview, and our newest presentation on our IR website. With me today from Tempus are Eric Lefkofsky, our Founder and CEO, and Jim Rogers, our CFO. Before we get started, I want to remind everyone that management might make forward-looking statements on this call, and those statements carry risks and uncertainties that could lead actual results to differ materially; please see our 10-K and other subsequent filings with the SEC for a discussion of those risks. We will also discuss non-GAAP financial measures during the call, and those are not prepared in accordance with generally accepted accounting principles. Definitions of these non-GAAP financial measures, together with reconciliations to the most directly comparable GAAP financial measures, appear in our earnings release, which you can access on our IR page. I'd now like to hand the call over to Eric.

Eric Lefkofsky

executive
#2

Thanks. Hello, everyone. We had an excellent quarter. Our revenue came in at $348.1 million, which is up slightly more than 36% compared to a year ago. Diagnostic revenue reached $261.1 million, reflecting growth of nearly 35%, fueled by especially robust performance in oncology, where unit growth was roughly 28%. Strength was broad-based, with solid tumor and liquid biopsies doing well and MRD volume doing even better. Hereditary decelerated somewhat, which we anticipated since we're up against some very high growth rates from the prior year; we look for that business to get back to mid-teens in the back half of the year. Our data and applications business performed exceptionally well. Revenue of $87 million, a 40.5% increase year-over-year, with notable momentum in data licensing and modeling business insights, which was up more than 44%. This marks our third consecutive quarter with bookings above $100 million, as TCV climbs and visibility for our data and apps business is the strongest it has been in a long while. Overall, the business is performing very well. Our core businesses are at or ahead of plan. We're set up for a strong year. Consequently, we raised our guidance to a range of $1.59 billion-$1.6 billion for the year, with adjusted EBITDA of roughly $65 million. With that, I'm happy to take your questions.

Kallum Titchmarsh

analyst
#3

Thanks, that's a good one. Eric, I'd like to begin on the insights side, especially with everything that's come out recently. Could you walk us through how conversations with the big pharma accounts have been shaping up during this year, especially given the way interest in AI seems to be shifting? What I'm really wondering is where de-identified data falls within their list of priorities. Obviously, those of us on the investor side are paying attention to when the larger contracts close and come up for renewal. So we'd love your current perspective on how long these deals can last and how much room there is to extend them. Thanks.

Eric Lefkofsky

executive
#4

Sure. What I'd say is that every one of our major big data partnerships remains quite solid. When these agreements come up again, we've consistently renewed them at levels equal to or better than what they were before. We're very confident that pattern will hold. Another thing that matters just as much, maybe more, is that we keep bringing genuinely significant new companies into that elite roster. In this quarter by itself, Merck came on board, and they committed to a sizable strategic collaboration with us. We also broadened the tie-up we have with Gilead. Several others are at advanced stages; the pipeline we have is genuinely deep and strong. As I mentioned in the letter, look, I don't believe anybody expected our data operation and our modeling operation to reach this size, to expand this fast at this size, or to prove this resilient. To me, one of the most remarkable aspects of it is reaching these enormous heights where, you know, organizations commit $100 million plus to license de-identified data from you across a span of multiple years. Doing that with a single pharma company would be, I think, you know, quite striking, and doing it with a pair is even more so. At this point we have close to six companies at that tier, signing these enormous strategic agreements, with additional ones on the way. My expectation is that eventually, that group becomes the overwhelming majority of all big biotech and big pharma; there's a shift underway in which licensing our data is no longer the only thing they do. Increasingly, they're actually constructing models alongside us, whether that means foundation models, the way AstraZeneca does it, or smaller models that draw on our data. Our database is now extremely large, past 500 PB; all of it links into this analytics and model building platform, which now connects not only to CPUs but to GPUs as well. More and more, companies are creating proprietary models so they can sharpen their own internal R&D efforts, and that movement appears to be heading up and to the right.

Matt Shea

analyst
#5

Appreciate you fitting us in. Matt Shea here, filling in for Ryan. Eric, to build on what was just asked, regarding those two recent agreements—one with Gilead, the other with Merck—is there anything worth flagging about their size or scope that sets them apart from your other strategic partnerships, or simply anything notable you'd want to mention about those two wins specifically? Jim, once you add the Merck and Gilead deals to the $350 million in TCV already set aside for 2026 revenue, how confident are you in reaching that implied $410 million data revenue target, and where might there be room to exceed it?

Eric Lefkofsky

executive
#6

Sure, I'll take that first part. The Merck arrangement is a major strategic collaboration focused on data and modeling. We already have sizable partnerships with companies such as AstraZeneca, GSK, and BMS. This one ranks right up there in scale with those. What makes it different is that we only have a limited number of deals this size, though as I said earlier, it's considerably bigger than most of the others. It's really encouraging to watch organizations reach a point where they start engaging strategically, with focused groups, plenty of information, wide-reaching permissions, and yes, developing AI models and everything else that supports a durable, lasting partnership. Now Gilead stands out as somewhat distinct. They're sizable — not as big as Merck, yet still substantial. The exciting part is that this marks a major jump beyond what they've done before. There are two things we're keeping an eye on, correct? Our clear goal is reaching a stage where we hold contracts worth over $100 million with the largest possible number of major pharmaceutical companies and large biotechs. Beyond that, we want those relationships to expand, since landing at that strategic tier right away rarely happens for us. It requires time. As we've explained in past discussions, the usual pattern is beginning with a single project, possibly focused on one subtype, before eventually handling several subtypes along with multiple other projects. In the end, it dawns on folks that our data can make them much smarter about which compounds are actually worth investigating, how they shape phase I and phase II trials to maximize the odds of success, how they go about enrolling patients, and how they confirm a product can succeed commercially. They're applying what we provide throughout that whole range, and building comfort takes a while. So it's encouraging to watch a company like Gilead raise its commitment so dramatically compared with what it has done in the past.

Jim Rogers

executive
#7

When it comes to visibility, as we said on the year-end call, we had roughly $350 million in TCV tied to 2026. That gave us a huge amount of confidence going into the guidance. Beyond that, we could see a very robust pipeline. Merck and Gilead are clearly among the deals in that pipeline that came through in the first quarter. That lifts our visibility further, and the pipeline is still solid, just as Eric pointed out. The insight business, you know, is truly doing remarkably well right now. Never before have we reached this stage of the year with this much clarity on the overall figure. That's thrilling for 2026, and equally for 2027 and past that. As Eric mentioned, our TCV in fact rose during the first quarter, which is remarkably impressive when you consider that you're bringing in $80 plus million of revenue while still expanding that backlog that will feed revenue for the rest of the year and across the next several years ahead.

Subbu Nambi

analyst
#8

Hi there, everyone. I appreciate you letting me ask. This one's directed at Jim. Is there anything new regarding your xF FDA submission? I realize you repeated that it had been filed, but is there any practical schedule for an ADLT pricing update on this test? Also, might you split out for us how much of your data licensing mainly originates in oncology versus how much has arrived from other fields such as Rare Disease, cardiovascular? Over a longer horizon, how do you expect that blend to develop?

Jim Rogers

executive
#9

Much appreciated, Subbu, I'll begin with the FDA submissions, and then Eric is able to handle the question about the breakdown of the data. In a way, I would say there is nothing new on the xF submission that was filed earlier this year; we are waiting on feedback there. As we said before, we do not anticipate that having any effect on pricing or ASPs in 2026. Another item we highlighted in our letter concerns an amendment we are making to our xT FDA-approved assay, or the submission. An amendment was filed by us there that is going to cover tumor only, meaning situations where a normal sample is no longer obtained, or is not obtained. That is going to let us speed up the migration toward the ADLT version of the assay. We anticipate a decision there very soon; those represent the two major updates, or one major update, from an FDA perspective. Eric?

Eric Lefkofsky

executive
#10

Yes. Beyond pushing ASP upward in diagnostics, on the data front, the bulk of what we license right now centers on oncology and comes nearly completely — maybe even completely — out of our therapy selection operation. You know, we established a de-identified data operation by combining matched clinical molecular data, chiefly from therapy selection, meaning our liquid biopsy test and our solid tumor profiling test, and that database, which exceeds 500 PB, powers the great majority of our data business. It's been gratifying to see some recent wins in neurology, and specifically, we were just brought on to start developing a multimodal model focused on Alzheimer's disease. That project is worth multiple millions of dollars, we're in the thick of it at present, and we'll wrap it up around the middle of this year. We've got folks beginning to access the database in additional areas, but in our view, this really amounts to major long-term growth drivers. We can envision the data business — especially data and modeling in the U.S. — reaching $ multi-billion. My guess is that as we move into further disease areas, there's, you know, every sort of opportunity available, within the U.S. by itself, never mind internationally. Plenty of room to grow.

Subbu Nambi

analyst
#11

Thank you, guys.

Dan Brennan

analyst
#12

Great, thank you, and thanks for taking the questions. Perhaps I'll start with one about cash flow during the quarter. So how should we be thinking about this — cash flow from operations declined by roughly $70 million, give or take. My understanding is that you said free cash would come in somewhere near EBITDA, and that was a loss of about $3 million, I believe. What's the way to think about how free cash moves forward as the year unfolds? Maybe one more that's related — or actually not related, my apologies — you've now got xT FDA approved, and you're going to pursue getting xR FDA approved. Is there any shift in our capacity to submit separate claims for those two items to your regional MAC, should the jurisdiction shift for some reason and both products carry FDA approval? How should we view the sustainability of that arrangement moving forward? Thanks.

Jim Rogers

executive
#13

Sure, I'll handle the first question, and Eric can address the second. Regarding free cash flow, it ran somewhat high in Q1, which has been fairly standard for us across the past two years. There are a few factors at play. First, it's simply the timing around payables, along with bonuses being disbursed during Q1. In the letter, we mention that we expect a pretty meaningful step-up in Q2. That comes from two things: first, those payables getting back to normal, and second, several of our big insights contracts that previously involved prepayments or deferred revenue being drawn down will switch to being paid each quarter. So again, we're looking for a substantial gain in the second quarter, and after that, things should keep getting better as adjusted EBITDA rises. With that, I'll hand it over to Eric for the second one.

Eric Lefkofsky

executive
#14

Sure, we're in a solid position there, since we anticipate producing roughly $65 million in positive EBITDA, with each quarter showing a meaningful step up in performance. At this point we've got — I honestly don't even know — five, six, seven, eight consecutive quarters where EBITDA has improved quite substantially compared with the same quarter a year earlier. Our cash situation feels very strong to us; additional cash isn't necessary. There's nothing we need to do. From where we sit right now, quarter-to-quarter swings in cash flow aren't all that important. Cash will be generated, and we will be EBITDA positive. When it comes to funding the business, we don't require alternative financings. Right now, we're in a pretty good place. Regarding xT, xR, and xF, my guess is that eventually every one of our main assays will carry FDA approval. One is approved at present, and as Jim said, we're broadening it in solid tumor profiling. A second one is currently before the FDA in liquid biopsy. RNA will be taken to them too. My view is these developments won't change the way tests are ultimately ordered or billed. Ordering and billing happen individually and rest on medical necessity. Once ordered and billed, payment follows whatever payment mechanism applies; we do think ASPs will probably climb for years, because our present ASP is approximately $1,740, or something along those lines, somewhere around $1,720. Our expectation is roughly $500 of additional ASP increase across the next year or two, you know, as we secure FDA approval for all of these. Based on everything we can observe, the present trend is nothing other than substantially favorable.

Brad Bowers

analyst
#15

Thanks. Appreciate the question. I wanted to touch on what's happening with oncology genomics trends. It seems like we're seeing more headlines from competitors about companion diagnostic status wins. I was hoping to think through what that means for Tempus, especially as therapy selection becomes more broadly and formally written into labels as diagnostic companions to drugs. Maybe you could give an update on what inning of adoption we're in for therapy selection, and whether there's still a rising tide lifting all companies, or whether more formal partnerships are needed to sustain that 20% volume growth in that business? Thanks.

Eric Lefkofsky

executive
#16

Yeah, so honestly, CDXs have played a role in therapy selection for years now. There are plenty of them out there. They haven't changed how physicians order tests in the U.S., at least, because of the way drugs get paid for here and the way diagnostic tests get ordered. In other markets, where you can't access the drug unless that specific companion test is ordered, there could be an effect; here in the U.S., our system isn't structured that way. Actually, the movement has gone the opposite direction, with people increasingly looking to shift away from companions as a prerequisite for ordering. My suspicion is that whether we capture more CDXs or not, no matter who ends up winning CDXs, it won't move the needle on the group of companies that account for the overwhelming majority of external sequencing. I'd guess all of us will be just fine. The gap in growth rates, the fact that we're expanding faster than others, or than most others, in therapy selection, mostly comes down to the technology platform we've built, which is comprehensive and lets physicians do their jobs well, and we see nothing suggesting that's slowing. I don't think CDXs will affect it. As for where we stand, it still feels to us like we're, I don't know, perhaps early to the middle of the game when it comes to therapy selection. Some papers came out recently showing that a significant number of physicians still aren't ordering comprehensive genomic profiling when treating cancer patients. Plenty of patients historically haven't been profiled. I'd guess there's pretty solid unit volume growth ahead for the industry over the next, say, three to five years. I think we'll grow faster thanks to all the advantages built into our platform; it does feel like a healthy space for solid tumor profiling, liquid biopsy, and even healthier on the MRD side, since that's still fairly new.

Brad Bowers

analyst
#17

Thanks.

Kyle Mikson

analyst
#18

Hi, everyone. Appreciate the questions. Could you discuss what role Rare will play when it comes to the hereditary testing segment either holding at or returning to the mid-teens? Along those lines, would you expand on how xG has been growing, since I believe it was up 50% compared with a year earlier in Q1? Thanks.

Eric Lefkofsky

executive
#19

Well, xG, which is our germline assay, those percentages do carry weight, correct? Its size is limited. Our MRD assay, for instance, expanded 500%, yet that amounted to just 6,500 a test, so that's great, though percentages sometimes paint a misleading picture. Most of our HCT volume clearly sits with Ambry, considering how much hereditary volume they handle. Our suspicion is that since those units are so large, Rare essentially cannot shift the unit volume metric at all, correct? It does shift the revenue metric, since reimbursement per test comes in considerably higher, yet units prove difficult to shift. Our expectation of returning to mid-teens stems from the fact that we have long pointed out, or at minimum, have noted for quite a while, that we anticipated that business would grow at a mid-teens pace. It's now up against stretches of far stronger growth from last year, when that assay was expanding at roughly 40%. The thing is, it's somewhat lumpy. Their growth, you know, has come in lumps, and when you're comparing against stretches of lumpy growth, it stays lumpy. My guess is that once we reach the back half of the year, growth rates will come back to roughly mid-teens. Rare, I believe, will perform well too. Our first half of this year got off to a slower start. As GeneDx noted, I think, they moved a lot of volume over to whole genome, which carries some ASP consequences for them. Getting that product to market happened a bit later on our end, so for us, the problem has leaned more toward volume. We haven't been selling many tests. Once our product reaches market, we anticipate some of the, you know, some of those volumes will improve, and clearly, even at $3,000 or whatever the ASP happens to be, it will remain ASP accretive for us. I'd say the back half of the year appears far stronger for our hereditary business, since we're up against slower growth stretches from last year, while Rare begins to genuinely gain traction. My bet is that by year's end, that business will be feeling quite good.

Mark Schappel

analyst
#20

Hi, thanks for fielding my question. Eric, during the prepared remarks it was pointed out that you have an attach rate of about 40% for your algos — I believe that was regarding your solid tumor assays in oncology. I'm curious whether you might unpack a bit more which products are behind those increased attach rates, and perhaps what makes you confident that you can grow that further over the coming 12 months or so.

Eric Lefkofsky

executive
#21

Yeah. Over the years we've developed a range of algorithms. A few of them, for instance, include our homologous recombination deficiency algorithm and our Tumor Origin algorithm, where, you know, for roughly 5% of cancer patients, the site of primary diagnosis is unknown to us. Using our transcriptomic assay, our RNA assay, we're actually able to predict that with extremely high fidelity. We also have an Immune Profile Score that essentially You know, normally you'd rely on something like tumor mutational burden as a litmus test — if you were TMB high, you'd receive a checkpoint inhibitor; if not, you wouldn't — and that test isn't perfect, but our Immune Profile Score actually improves upon it. It turns out a substantial group of people would in fact benefit from an immunotherapy yet never receive it, and similarly, a group that appears as though they would respond to immunotherapy actually doesn't, so we're able to predict that. As these algorithms essentially become ordered more and more widely, they're simply one more instrument within this broader collection of, you know, sort of technology-enabled assets that our physicians lean on increasingly. They're able to do all sorts of things that aren't possible with others. When you look at We flagged this years ago. We told people, like, "We're going to see significant growth rates over time." I think it, you know, a couple of years back people were saying, "I don't see it," but, you know, now it's like years behind us. As much as we flagged years ago that technology would drive a bunch of ordering behavior, I think we've simply proven that. Physicians are overworked, they're seeing a huge number of patients, they lack the time in the day to do their job, and those companies capable of helping them make decisions, analyze real-time data, arrive at the right answer, so on and so forth, they're simply going to flock to that platform, just as you and I flock to Amazon. If it's convenient and easy, and I get everything I need, that's going to drive my behavior. We don't see that trend slowing down. Actually, a key factor behind our move into MRD and also into hereditary testing is our conviction that this will prove correct for every significant assay in oncology — from determining whether my patient faces risk, to choosing how they should be treated once disease appears, to figuring out how I track them after treatment. Our aim is to be comprehensive, to be, you know, woven into the workflow, and to assist doctors in making data-driven choices in real time, and all of that is fueling our expansion.

Mark Schappel

analyst
#22

Thanks.

Casey Woodring

analyst
#23

Excellent, and thanks for fielding these. Perhaps this ties into what Dan asked before — your guidance calls for adjusted EBITDA of $65 million during this year, yet in the quarter just reported it came in at negative $3 million. Could you take us through your expectations for how EBITDA will build across the year, along with the pattern for gross margins and operating expenses? Second, regarding MRD, I'd be interested in your current view on when volumes there will genuinely begin to accelerate. Thanks.

Jim Rogers

executive
#24

I'll handle the adjusted EBITDA piece, and then Eric can address MRD. Much like the prior year, the progression should build as the months pass. In Q1 we saw roughly $13+ million of year-over-year improvement. Q2 should look much the same. Clearly, the second half carries more weight for data, and that drives wider margins and a greater amount falling through to the bottom line. As we noted early in the year, we're lucky to be producing substantial gross profit dollars, which fund a number of the investments needed to deliver growth over the long term. Our aim is to keep demonstrating better operating leverage, and we believe we're positioned to do exactly that.

Eric Lefkofsky

executive
#25

When it comes to MRD, the growth has been genuinely strong. As we mentioned, I believe, on the prior call, we're achieving these results with a quite limited sales team focused on MRD; we haven't yet opened this up across our full sales organization, which numbers in the hundreds. Part of the reason is that the unit economics are better once reimbursement comes through, and roughly 97% of our tests are tumor-informed, so Personalis is truly bearing that reimbursement weight. They've got a handful of indications cleared, but many additional ones are in the works. Once they secure a more complete reimbursement package that resembles Natera's in appearance and feel, it becomes very difficult to release all of that volume, since we'd simply be creating an enormous loss for them. If we ramped things up 10x, their cash burn would climb substantially. We need to pace it, which is what we're doing, and we're doing it in tight coordination with them. As reimbursement gets better over time, you'll see us keep expanding that more aggressively. My guess is you can just, you know, sort of run the numbers yourself, correct? I mean, if we truly devoted a lot of resources to this, we'd be an extremely formidable MRD competitor in the United States.

Dan Arias

analyst
#26

Yes. Hey, everyone. Appreciate you taking the questions. Eric or Jim, I'm looking at the slide deck you've got here, and there's one slide mentioning an expectation of 25% top-line growth across the coming three years. But another slide in there discusses ASP possibly being 30% higher. I realize it's illustrative, and the real aim seems to be highlighting the EBITDA trend, but what would be either an underlying volume trend or simply a revenue trend that factors in some of these ASP items we ought to consider? Does that 25% you mention include some amount of ASP increase?

Eric Lefkofsky

executive
#27

Yes, I mean, there are always puts and takes. One thing I find really great about this company is that, if you've been tracking us over the past three or four years, you already know how this goes — it's always something new with us. At this point, our guidance comes in at about $1.6 billion. It's worth remembering that only three or four years ago, our revenue was in the $300 million to $400 million range. Back then we were a pretty tiny operation. Since then, we've delivered major growth and kept it under control. We've been giving guidance for quite a while; these days it's a narrow band, whereas in the past it was simply a single figure. The explanation for our ability to speak with some precision here is that this company is built to last, and we have many levers within our control. Certain ones break in our favor; others do not. Jim and I have been doing this for many years now. Not once has a quarter arrived in which every single thing broke our way. There is always something that goes against us. Fortunately, when you add it all up, the items moving upward and to the right outnumber those that aren't, and that is what you get from a diversified operation with a variety of growth engines and growth levers. For our part, we believed we could confidently announce to everyone that we're targeting 25% growth—not merely across a single year, but spanning three years. Given how large we already are, that figure carries real weight. Honestly, I haven't actually calculated it, yet going from $1.6 billion up to roughly $2 billion, then $2.5 billion or $3 billion, it ends up being quite a substantial amount. Average selling prices should rise, and we should see gains in units and volume too. Certain factors will break in our favor, while others won't. Sure, there will be shifts in the market, changes in the weather, and all sorts of other variables. But when you step back and look at the whole picture, we've created a company that's strong enough to handle them. Our diagnostics portfolio is wide-ranging—it covers everything from hereditary conditions to choosing treatments, from MRD to other illness categories such as Rare Disease, and much more—plus we have a very solid data and applications operation. Whatever happens, we feel fortunate, because we're quite sure we can maintain healthy growth.

Jim Rogers

executive
#28

Dan, the sole point I'd tack on is this: nothing is being suggested about volumes just because we've got that reimbursement upside. Clearly, with reimbursement gains, nailing down precisely when they'll land is tough. As you know, our volume patterns remain really robust. Those two lines in the deck aren't hinting at anything.

Liz Krutoholow

executive
#29

Thanks, everyone, for being here today. We’re looking forward to talking with you once more in a few weeks at our Investor Day. Have a great day.

Operator

operator
#30

Everyone, that brings us to the end of today's session. Thanks to each of you for being here. You're welcome to hang up now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Tempus AI, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Tempus AI, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Tempus AI, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.